Article Per Year (5 Year)
p-Index From 2020 - 2025
0.778
P-Index
This Author published in this journals
All Journal Jurnal Ners Scientific Journal Jurnal Ilmu Kesehatan Indonesia (JIKSI) Journal of Pharmaceutical and Sciences.
Lydia Susanti, Lydia
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Spasmofilia dengan Hipoparatiroidisme Pasca Tiroidektomi Susanti, Lydia; Indra, Syarif; Noza, Aulia
Scientific Journal Vol. 1 No. 4 (2022): SCIENA Volume I No 4, July 2022
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (577.766 KB) | DOI: 10.56260/sciena.v1i4.57

Abstract

Spasmofilia merupakan keadaan patologis dimana terjadi hiperiritabilitas saraf dan otot (neuromuskular) akibat adanya gangguan keseimbangan elektrolit,  terutama ion kalsium (Ca2+) dan ion magnesium (Mg2+) yang ditandai dengan munculnya kedutan otot, kesemutan dan spasme karpopedal. Hipoparatiroidisme merupakan keadaan dimana produksi hormon paratiroid yang tidak adekuat. Keadaan ini jarang ditemukan dan umumnya disebabkan oleh kerusakan atau pengangkatan kelenjar paratiroid pada saat operasi tiroid. Laporan kasus ini  membahas mengenai pasien perempuan berusia 25 tahun dengan spasmofilia  dan hipoparatiroidisme sekunder  ec tiroidektomi.
Gambaran Elektrodiagnostik pada Polineuropati Susanti, Lydia; Adhi Putri, Fanny; Yusran, Andi Fadilah
Scientific Journal Vol. 1 No. 5 (2022): SCIENA Volume I No 5, September 2022
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (417.294 KB) | DOI: 10.56260/sciena.v1i5.58

Abstract

Banyaknya jenis kelainan saraf perifer dengan gejala yang tidak jauh berbeda menyebabkan tidak mudah untuk menegakkan diagnosis gangguan sistem saraf perifer. Pemeriksaan elektrofisiologi dapat dilakukan sebagai salah satu pemeriksaan penting dalam penegakkan diagnosis gangguan sistem saraf perifer,. Pemeriksaan elektrofisiologi yang akan dilakukan disesuaikan dengan kebutuhan penengakan diagnosis, artinya berbeda diagnosis maka berbeda juga pilihan pemeriksaan elektrofisiologi yang dilakukan.  Polineuropati adalah sebuah gangguan menyeluruh dari sistem saraf perifer. Prevalensi kejadian polineuropati sekitar 5%-8%, dan menggambarkan gangguan yang paling umum dari kelompok kelainan ini. Gangguan ini dapat memiliki banyak etiologi dan penyakit penyerta lainnya, dan dalam praktek klinis, hampir seluruh spesialis medis dapat berkontak dengan pasien polineuropati ini. Pemeriksaan penunjang seperti pemeriksaan elektrodiagnostik dibutuhkan dalam penegakkan diagnosis sebelum memulai terapi definitif. Pemeriksaan ini juga dapat membantu membedakan onset akan kejadian polineuropati yang diderita pasien.
Efektivitas Plasmaferesis Sebagai Terapi Pada Miastenia Gravis: Sebuah Tinjauan Naratif Azzati, Normaida Baizura; Permana, Hendra; Almurdi, Almurdi; Susanti, Lydia; Alioes, Yustini; Yusri, Elfira
Jurnal Ilmu Kesehatan Indonesia Vol. 6 No. 1 (2025): Maret 2025
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jikesi.v6i1.1390

Abstract

Latar Belakang: Miastenia gravis adalah penyakit neurologi autoimun yang jarang terjadi, namun sangat mempengaruhi kualitas hidup pasien dikarenakan tingkat keparahan yang cukup tinggi. Plasmaferesis digunakan sebagai salah satu pilihan terapi pada kondisi ini. Objektif: Tinjauan Naratif ini bertujuan untuk menilai penelitian terkait efektivitas terapi plasmaferesis terhadap miastenia gravis. Metode: Penelitian ini merupakan tinjauan literatur terhadap 7 artikel penelitian yang dipublikasi pada rentang tahun 2019-2023. Sumber pangkalan data yang digunakan adalah Pubmed, Science Direct, dan ProQuest. Artikel dilakukan penyeleksian berdasarkan kriteria eligibilitas yang telah ditentukan. Hasil: Menurut artikel yang dilakukan tinjauan, diketahui bahwa plasmaferesis dapat memberikan luaran klinis yang baik pada pasien. Plasmaferesis juga mampu meningkatkan kualitas hidup pasien secara signifikan. Kesimpulan: Semua literatur sepakat menyatakan bahwa plasmaferesis efektif digunakan sebagai terapi pada miastenia gravis.
Plasma pTau181 dan Gejala Neuropsikiatri pada Demensia Alzheimer: Sebuah Studi Cross-Sectional Fadhilah, Nailatul; Syafrita, Yuliarni; Susanti, Restu; Indra, Syarif; Susanti, Lydia; Putri, Fanny Adhy
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 4 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i4.1143

Abstract

Alzheimer’s disease is the leading cause of dementia, marked by progressive cognitive decline and neuropsychiatric disturbances collectively known as behavioral and psychological symptoms of dementia (BPSD). Plasma phosphorylated tau at threonine-181 (pTau181) has emerged as a minimally invasive biomarker of tau-related neurodegeneration, but its association with BPSD remains uncertain. This study investigated the relationship between plasma pTau181 levels and BPSD in Alzheimer’s dementia. An analytical observational study with a cross-sectional design was conducted in patients clinically diagnosed with predefined eligibility criteria. Plasma pTau181 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), while BPSD was assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Statistical analyses were performed to examine associations between plasma pTau181 and BPSD status. Plasma pTau181 levels ranged from 4.32 to 97.23 pg/mL, with a median plasma pTau181 level of 19.29 pg/mL (IQR: 11.81-25.05) in patients without BPSD and 20.67 pg/mL (IQR: 11.81-43.41) in those with BPSD. No significant differences in pTau181 levels were observed between patients with and without BPSD (p = 0.310). These findings suggest that plasma pTau181 may not be directly related to the presence of BPSD in Alzheimer’s dementia. While plasma pTau181 remains a promising biomarker of tau pathology, its predictive value for neuropsychiatric symptoms appears limited. Longitudinal studies are needed to explore its role in BPSD pathophysiology further.
The Relationship Between Serum Calprotectin Levels and Severity in Myasthenia Gravis Patients at Dr. M. Djamil Hospital Padang Lestari, Novia Riza; Susanti, Lydia; Syafrita, Yuliarni; Susanti, Restu; Bestari, Reno; Sutia, Dedi
Jurnal Ners Vol. 10 No. 1 (2026)
Publisher : Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/jn.v10i1.51684

Abstract

Myasthenia Gravis (MG) is an autoimmune disorder characterized by skeletal muscle weakness resulting from impaired neuromuscular transmission, primarily caused by autoantibodies directed against acetylcholine receptors. Excessive immune activation in MG triggers the release of inflammatory mediators, one of which is calprotectin — a protein complex of S100A8/A9 that is released by neutrophils and monocytes during the inflammatory process. Elevated levels of calprotectin have been reported in various autoimmune diseases; however, the relationship between serum calprotectin concentration and disease severity in MG, based on the Myasthenia Gravis Foundation of America (MGFA) classification, has not been extensively investigated. The objective of this study was to determine the association between serum calprotectin levels and disease severity in patients with MG. This study employed a cross-sectional design involving 23 MG patients receiving treatment at Dr. M. Djamil Hospital, Padang, from May to July 2025. Serum calprotectin levels were measured using the ELISA method, while MG severity was assessed using the MGFA scoring system. Statistical analyses were performed using SPSS version 27.0, with a significance level set at p < 0.05. The results of this study showed that serum calprotectin levels in patients with Myasthenia Gravis (MG) tended to be higher than in the healthy population; however, there was no significant association with the Myasthenia Gravis Foundation of America (MGFA) severity classification (p = 0.276).
Co-Authors Adhi Putri, Fanny Almurdi Almurdi Azzati, Normaida Baizura Bestari, Reno Hendra Permana Indra, Syarif Lestari, Novia Riza Nailatul Fadhilah Noza, Aulia Putri, Fanny Adhy Restu Susanti Sutia, Dedi Yuliarni Syafrita Yusran, Andi Fadilah Yusri, Elfira Yustini Alioes